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Abstract
Purpose Epicardial adipose tissue (EAT) has been linked to
coronary artery disease (CAD) and coronary microvascular
dysfunction. However, its injurious effect may also impact
the underlying myocardium. This study aimed to determine
the impact of obesity on the quantitative relationship between
left ventricular mass (LVM), EATand coronary microvascular
function.
Methods A total of 208 (94 men, 45 %) patients evaluated for
CAD but free of coronary obstructions underwent quantitative
[15O]H2O hybrid positron emission tomography (PET)/CT
imaging. Coronary microvascular resistance (CMVR) was
calculated as the ratio of mean arterial pressure to hyperaemic
myocardial blood flow.
Results Obese patients [body mass index (BMI)>25, n=133,
64 % of total] had more EAT (125.3±47.6 vs 93.5±42.1 cc,
p<0.001), a higher LVM (130.1±30.4 vs 114.2±29.3 g,
p<0.001) and an increased CMVR (26.6±9.1 vs 22.3±
8.6 mmHg×ml−1×min−1×g−1, p<0.01) as compared to
nonobese patients. Male gender (β=40.7, p<0.001), BMI
(β=1.61, p<0.001), smoking (β=6.29, p=0.03) and EAT
volume (β=0.10, p<0.01) were identified as independent
predictors of LVM. When grouped according to BMI status,
EAT was only independently associated with LVM in
nonobese patients. LVM, hypercholesterolaemia and coronary
artery calcium score were independent predictors of CMVR.
Conclusion EAT volume is associated with LVM indepen-
dently of BMI and might therefore be a better predictor of
cardiovascular risk than BMI. However, EAT volume was
not related to coronary microvascular function after adjust-
ments for LVM and traditional risk factors.
Keywords Coronarymicrovascular function . Epicardial
adipose tissue . Left ventricular mass . Obesity . [15O]H2O
Positron emission tomography
Introduction
Left ventricular mass (LVM) has been shown to be a strong
predictor of adverse cardiovascular outcomes and has been
demonstrated to remain a potent prognosticator even after
the adjustment for hypertension and other traditional risk fac-
tors [1]. There is a large body of literature documenting an
increase in LVM in obese individuals [2, 3]. While the
aetiology of this link between obesity and LVM remains elu-
sive, the visceral fat between the myocardium and visceral
pericardium known as epicardial adipose tissue (EAT) may
be a potential contributing factor. Like visceral abdominal
fat, EAT appears to be increased in obesity [4, 5]. It has pre-
viously been demonstrated that EAT plays a role in coronary
atherosclerosis through a paracrinemanner, by the secretion of
pro-inflammatory cytokines [6]. These local effects, however,
may not be limited to the coronary vasculature and may also
influence the underlying myocardium [7]. Indeed, there is
some evidence that EAT contributes to LV remodelling and
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Iacobel l i s et a l . showed a rela t ionship between
echocardiographically measured EAT and LVM in healthy
volunteers [8]. Furthermore, EATwas also found to be predic-
tive of an impaired coronary vasodilator capacity in patients
without obstructive coronary artery disease (CAD) [9, 10];
hence, a key role of EAT in the development of coronary
microvascular dysfunction has been postulated. However, per-
suasive studies on the quantitative relationship between EAT,
LVM and coronary microvascular function are lacking. There-
fore, the present study aimed to determine the relationship
between EAT, LVM and coronary microvascular function, as
measured by hybrid [15O]H2O positron emission tomography
(PET)/CT imaging, in patients evaluated for CAD in whom
haemodynamically significant disease was excluded.
Materials and methods
Patient population
Data were retrospectively obtained from a clinical cohort
of patients being referred for cardiac hybrid [15O]H2O
PET/CT imaging because of symptoms suggestive of an-
gina pectoris or a high risk profile (i.e. presence of two or
more risk factors in the absence of symptoms). Hyperten-
sion was defined as a blood pressure of≥140/90 mmHg or
the use of antihypertensive medication. Hypercholesterol-
aemia was defined as a total cholesterol level of≥5 mmol/
l or treatment with cholesterol-lowering medication. Pa-
tients were classified as having diabetes if they were re-
ceiving treatment with oral hypoglycaemic drugs or insu-
lin. A history of smoking was allocated to all current and
former smokers. A positive family history was defined as
having at least one first-degree relative with CAD before
the age of 55 in a male or below the age of 65 in a female
relative. Obesity was defined as a body mass index
(BMI)≥25. Patients with cardiomyopathy, impaired LV
function and/or a documented history of CAD were ex-
cluded. A history of CAD was defined as a previous myo-
cardial infarction, percutaneous coronary intervention or
coronary artery bypass graft surgery. Furthermore, pa-
tients with obstructive CAD on coronary computed to-
mography angiography (CCTA) were excluded. Obstruc-
tive CAD on CCTA was considered to have been ruled
out on a CT scan of sufficient quality enabling adequate
grading of all major coronary segments, which did not
display a stenosis≥50 %. A total of 217 patients met this
criterion. To ensure the exclusion of myocardial ischae-
mia, patients were only eligible for the study if they had
no coronary calcifications (coronary calcium score=0)
and absence of non-calcified coronary plaques [11]. If
not, only patients with hyperaemic myocardial blood flow
(MBF) values>2.3 ml×min−1×g−1 were included. In the
presence of abnormal myocardial MBF, non-obstructive
CAD (<50 % stenosis) on the invasive coronary angio-
gram was considered to adequately rule out functionally
relevant epicardial disease. Finally, patients with evidence
of coronary atherosclerosis, but who were referred for
screening purposes only and who had no chest discom-
fort, were also included in the study. In 9 of the initial 217
patients haemodynamically significant CAD could not be
excluded with certainty and they were therefore excluded
from the analysis. As such, a total of 208 patients met the
inclusion criteria and are described in the present study. A
flowchart of the inclusion process is demonstrated in
Fig. 1. The pretest likelihood of CAD was determined
using the Diamond and Forrester score, using <13.4 % ,
13.4–87.2 % and >87.2 % as cut-off values for low, in-
termediate and high likelihood for CAD, respectively
[12]. The requirement for informed consent was waived
by the Ethics Committee due to the retrospective nature of
the study.
Scan protocol
All patients underwent a PET/CT scanning protocol for the
concomitant evaluation of coronary anatomy and myocardial
perfusion. All patients were instructed to refrain from caffeine
and xanthine derivates 24 h prior to the scans. The hybrid
PET/CT imaging protocol is shown in Fig. 2 and has been
described in detail previously [13, 14].
Cardiac CT
After a scout CT for patient positioning all patients underwent
a non-contrast CT scan for coronary artery calcium (CAC)
scoring followed by a CCTA scan. A bolus of 100 ml iodin-
ated contrast agent (Xenetix 350, Guerbet, Paris, France) was
injected intravenously at an injection rate of 5 ml×s−1 follow-
ed by a 50-ml saline chaser. A standard scanning protocol was
applied, with 64×0.625 mm section collimation, 420-ms gan-
try rotation time, 120-kV tube voltage and a tube current of
800–1,000 mA, depending on the patient’s body size. The
automatic bolus triggering technique was used to initiate im-
age acquisition. To reduce radiation dose, an ECG-gated tube
current modulation was used. EATwas measured on the non-
contrast CT images using dedicated volumetric software
(Philips IntelliSpace workstation v5.0, Philips Healthcare,
Best, The Netherlands). The most cranial slice was at the level
of the pulmonary trunk bifurcation, and the most caudal slice
was identified as the last slice in which the posterior descend-
ing artery was visible. The method for quantifying EAT vol-
ume has been described in detail previously [15]. An example
of EAT quantification is shown in Fig. 3. In addition, LVM
was automatically segmented from the CCTA images. All
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analyses were performed on a Philips IntelliSpace workstation
v5.0 (Philips Healthcare, Best, The Netherlands).
PET imaging
The CCTA protocol was followed by PET myocardial perfu-
sion imaging (Fig. 2). After the injection of 370 MBq of 5 ml
[15O]H2O at a rate of 0.8 ml×s
−1 bolus, which was immedi-
ately followed by a 35-ml saline flush (2 ml×s−1), a 6-min
emission scan was started during resting conditions. This dy-
namic scan sequence was followed immediately by a
respiration-averaged slow low-dose CT scan to correct for
attenuation. After an interval of 10 min to allow for decay of
radioactivity, adenosine was administered intravenously to in-
duce hyperaemia. Two minutes after the start of intravenous
adenosine infusion of 140 μg×kg−1×min−1, a dynamic 6-min
PET sequence was started. All images were reconstructed
using the 3-D row action maximum likelihood algorithm into
22 frames (1×10, 8×5, 4×10, 2×15, 3×20, 2×30 and 2×
60 s), applying all appropriate corrections. Parametric MBF
images were generated and quantitative data were generated
using in-house developed software, namely Cardiac VUer
[16]. MBF was expressed in ml×min−1×g−1 of perfusable tis-
sue for each of the three vascular territories and for the entire
left ventricle.
Image interpretation
All CTscans were analysed by an experienced radiologist and
cardiologist. The axial slices were initially evaluated for the
presence of significant segmental disease and, additionally,
multiplanar and curved multiplanar reconstructed images
Non-obstructive CAD on CCTA
(< 50% stenosis)
No stenosis in





































Fig. 1 Flow diagram of patient
inclusion. Steps taken to exclude
any obstructive CAD among
patients. Patients were included if,
in addition to a negative CCTA
scan, they exhibited: (1) no
calcifications or (2) a normal
hyperaemic MBF or (3) a
negative invasive coronary
angiography or (4) no symptoms.
A total of 208 patients were
included in the study. CAD
coronary artery disease, CCTA
coronary computed tomography
angiography, CAC coronary
artery calcium, MBF myocardial
blood flow
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were used to determine stenosis severity. The coronary tree
was evaluated according to a 16-segment coronary artery
model modified from the American Heart Association [17].
CT-defined obstructive CAD was excluded if the segments
contained no CAD (no stenosis in combination with a CAC
score of zero) or non-obstructive CAD, which is defined as a
coronary stenosis causing a luminal diameter reduction<
50%. Two experienced readers visually graded the parametric
PET stress perfusion images for the presence of a perfusion
defect resembling myocardial ischaemia, according to the 17-
segment model of the American Heart Association [18]. After
visual assessment of the images, the readers interpreted the
quantitative perfusion data. The quantitative analysis allows
for the measurement of MBF for the calculation of coronary
flow reserve (CFR) and hyperaemic coronary microvascular
resistance (CMVR). The CFR is defined as the ratio of
hyperaemic MBF to baseline perfusion, whereas CMVR
was determined by dividing mean arterial pressure by
hyperaemic MBF [19]. For the exclusion of myocardial is-
chaemia due to flow-limiting epicardial lesions, a hyperaemic
MBF value<2.3 ml×min−1×g−1 was considered abnormal.
This cut-off value has previously been determined against a
background of fractional flow reserve [20]. These quantitative
results were combined with the visual grading of PET images
and in conjunction with the coronary anatomy as obtained
with CCTA to obtain a hybrid interpretation.
Statistical analysis
All continuous variables are reported as mean values±stan-
dard deviation (SD) and categorical variables are presented as
their actual value and percentage of group total. Evaluation of
Fig. 2 Hybrid PET/CCTA protocol. After a scout CT for patient
positioning a non-contrast (calcium scoring) and contrast-enhanced CT
scans were sequentially performed. This was followed by a [15O]H2O
PET myocardial perfusion scan in resting conditions and a low-dose CT
scan for attenuation correction. A minimum of 10 min after the first dose
of [15O]H2O, to allow for radiation decay, an identical PET sequence was
commenced for hyperaemic perfusion. Adenosine infusion at
140 μg×kg−1×min−1 was started 2 min before the start of the dynamic
PET sequence
Fig. 3 Example of EAT quantification in one axial slice. The pericardium
was identified (a) and traced manually (b). The adipose tissue within the
region of interest (indicated in blue) was then automatically quantified
and multiplied by the slice thickness (2.5 mm) (c). Summing the EAT of
all slices between the pulmonary trunk and lowest slice showing the
posterior descending artery gave the total EAT volume. All
measurements were performed using Phillips IntelliSpace workstation
v5.0 (Philips Healthcare, Best, The Netherlands)
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relationships between variables was performed using Stu-
dent’s t tests, chi-square tests and Pearson’s correlation anal-
yses. For reproducibility analyses, inter- and intraobserver
correlations were assessed using intraclass correlation coeffi-
cients in 53 randomly selected patients. Linear regression
models for outcome LVM were constructed, including the
following parameters in the univariable and multivariable
analyses: traditional risk factors (including age, gender,
BMI, hypercholesterolaemia, hypertension, smoking, family
history and diabetes), CAC and EAT. Linear regression anal-
yses for outcome CMVRwere performed with traditional risk
factors, CAC, EAT, and LVM. For heterogeneity estimation,
analysis of variance (ANOVA) was used to compare
hyperaemic MBF per coronary artery. Additionally, coeffi-
cients of variation (COV) were calculated by dividing the
SD of hyperaemic MBF by the mean hyperaemic MBF on a
per-coronary basis. A two-sided p value of <0.05 was consid-
ered significant. Statistical analyses were performed with IBM
SPSS Statistics version 20 (IBM SPSS Statistics, IBM Corpo-
ration, Armonk, NY, USA).
Results
Baseline characteristics
Baseline patient data are listed in Table 1 (demographics) and
Table 2 (imaging characteristics). A total of 208 patients are
described in the current study of whom 133 (64 %) had a
BMI≥25. Obese patients had a higher LVM (130.1±30.4 vs
114.2±29.3, p<0.001), more EAT (125.3±47.6 vs 93.5±
42.1, p<0.001), a lower hyperaemic MBF (3.23±1.42 vs
3.80±1.42, p<0.01) and a higher CMVR (26.6±9.1 vs 22.3
±8.6, p<0.01) as compared to the nonobese patients.
Homogeneity of perfusion
The mean hyperaemic MBF did not differ per coronary artery
(p=0.64) and was 3.44±1.34 (COV=38.9 %), 3.39±1.27
(COV=37.6 %) and 3.51±1.28 (COV=36.4 %) for the left
anterior descending artery, right coronary artery and circum-
flex coronary artery, respectively (Table 3). The distribution of
hyperaemic MBF per coronary is shown in Fig. 4.
Determinants of LVM
A significantly positive correlation between EAT and LVM
was observed for obese (R=0.44, p<0.001) and nonobese
(R=0.34, p<0.001) patients (Fig. 5). Results of univariable
linear regression analysis are listed in Table 4. After adjust-
ment traditional risk factors and the CAC score, multivariable
regression analysis (R2=0.61) showed male gender (β=40.7,
p<0.001), BMI (β=1.61, p<0.001), smoking (β=6.29, p=
0.03) and EAT (β=0.10, p<0.01) to be independent predic-
tors of LVM (Table 4). Of note, when performing the multi-
variable regression analysis according to BMI groups, EAT
was only independently associated with LVM in nonobese
patients (β=0.23, p<0.001), whereas in obese patients male
gender (β=44.2, p<0.001) and BMI (β=2.03, p<0.001) were
predictive of LVM. For both male and female patients, BMI
and EAT were identified as independent predictors of LVM,
while smoking was identified as a predictor of LVM in female
patients only (Supplementary Table 1).
Determinants of CMVR
There was a significant correlation between CMVR and EAT
in obese patients only (R=0.25, p<0.001). A significant in-
crease in CMVRwas observed with rising LVM in both obese
(R=0.48, p<0.001) and nonobese patients (R=0.32, p<0.01,
Fig. 5). Table 5 lists the univariable linear regression analysis
for CMVR. Multivariable linear regression analysis revealed
that hypercholesterolaemia (β=2.52, p=0.04), EAT (β=0.14,
p<0.001) and CAC (β=0.01, p<0.01) are predictive of
CMVR. When grouped according to BMI status, these same
risk factors remained significantly associated with CMVR in
the group of obese patients (Table 5). In the group of nonobese
patients, male gender (β=5.09, p<0.01) and smoking (β=
5.54, p<0.01) were independently associated with CMVR.
When, instead of CMVR, CFR was used as marker for coro-
nary function only age (β=−0.03, p<0.01) was identified an
as independent predictor for all patients (R2=0.06).When split
according to obesity status, age (β=−0.03, p<0.01) remained
the only parameter independently associated with CFR for the
group of obese patients (R2=0.05), whereas in the group of
nonobese patients no risk factors were found to be indepen-
dently associated.
Reproducibility of EAT measurements
The intraclass correlation coefficient of EAT volumemeasure-
ments assessed in 53 randomly selected patients were 0.98
(p<0.001) and 0.94 (p<0.001) for intra- and interobserver
variability, respectively.
Discussion
This study evaluated the relationship between EAT, LVM and
CMVR in symptomatic patients without obstructive CAD.
The main findings of this study are (1) a greater cardiac adi-
pose volume is independently associated with an increase in
LVM, (2) EAT is not predictive of coronary microvascular
function in symptomatic subjects without obstructive CAD
and (3) LVM is associated with coronary microvascular func-
tion independently of traditional risk factors and EAT volume.
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This study shows that an increase in EAT, the visceral fat
depot surrounding the heart, is significantly related to an in-
crease in LVM. This is in accordance with autopsy and echo-
cardiography studies showing an increase in LVM to be
strongly related to epicardial adipose mass, irrespective of
pathological cardiac conditions such as ischaemia and even
hypertrophy [8, 21]. Importantly, EAT rather than BMI is
more closely related to LVM, which is in line with the findings
of Iacobellis and colleagues [8]. Although BMI is considered
an important cardiovascular risk factor, the prediction of vis-
ceral tissue distribution by BMI, which is an indicator of total
adiposity, is governed by the contribution of subcutaneous
adipose mass and is therefore flawed [22]. Indeed, visceral
adipose tissue (VAT) burden or abdominal adipose tissue is
thought to possess a greater risk for the development of dia-
betes and CAD than BMI [23, 24]. This may be attributable to
its distinct functional and anatomical features, namely VAT is
more metabolically active and is characterized by a prominent
Table 1 Baseline patient characteristics




p value (between obese
and nonobese patients)
n=208 n=75 n=133
Male gender 94 (45 %) 30 (40 %) 64 (48 %) 0.31
Age 55.1±9.4 54.4±9.6 55.4±9.3 0.44
BMI 26.5±4.1 22.7±1.7 28.7±3.4 <0.001
Pretest likelihood for CAD 43.1±29.7 39.6±28.9 45.1±30.1 0.20
Low 33 (16 %) 15 (20 %) 18 (14 %) 0.24
Intermediate 157 (76 %) 55 (73 %) 102 (77 %) 0.62
High 18 (9 %) 5 (7 %) 13 (10 %) 0.61
Risk factors
Diabetes 32 (15 %) 3 (4 %) 29 (22 %) <0.001
Hypertension 69 (33 %) 15 (22 %) 54 (41 %) <0.01
Hypercholesterolaemia 60 (29 %) 13 (18 %) 47 (35 %) <0.01
Smoking 83 (40 %) 32 (43 %) 51 (38 %) 0.55
Family history of CAD 109 (52 %) 34 (46 %) 75 (57 %) 0.15
Reason for referral
Typical AP 56 (27 %) 18 (24 %) 38 (29 %) 0.52
Atypical AP 65 (31 %) 22 (29 %) 43 (32 %) 0.76
Aspecific AP 67 (32 %) 32 (43 %) 35 (26 %) 0.02
Screening/high-risk profile 20 (10 %) 3 (4 %) 17 (13 %) 0.05
BMI body mass index, CAD coronary artery disease, AP angina pectoris
Table 2 Baseline quantitative [15O]H2O PET/CT imaging results








LVM 124.4±30.9 114.2±29.3 130.1±30.4 <0.001
EAT volume 113.8±48.1 93.5±42.1 125.3±47.6 <0.001
CAC score 71.9±290.5 74.2±355.6 70.6±248.1 0.93
No calcifications
Myocardial perfusion
Resting MBF 1.07±0.46 1.11±0.4 1.05±0.52 0.37
Hyperaemic MBF 3.44±1.28 3.80±1.42 3.23±1.15 <0.01
CFR 3.44±1.29 3.60±1.36 3.34±1.25 0.18
CMVR 25.1±9.13 22.3±8.60 26.6±9.10 0.001
LVM left ventricular mass, EATepicardial adipose tissue,CAC coronary artery calcium,MBFmyocardial blood flow,CFR coronary flow reserve,CMVR
coronary microvascular resistance
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vasculature. Apart from its contiguity to the myocardium and
coronary arteries, EAT is in contrast to other visceral fat depots
not separated from the myocardium by fascia resembling
structures, allowing local paracrine interactions between
EAT and the underlying myocardium, rendering EAT most
likely a stronger correlate to LVM than general measures of
adiposity such as BMI [6]. The mechanism by which EAT
influences LV remodelling has not been unravelled yet, but a
mechanical and biochemical pathway have been postulated
[25]. First, EAT has been shown to reflect central obesity
and increased VAT volumes might therefore possess a greater
afterload to the left ventricle that comes along with an in-
creased LVoutput and stroke volume to enable adequate per-
fusion, prompting cardiac remodelling. Alternatively, there is
mounting evidence that EAT is a metabolically active organ
and an important source of pro- and anti-inflammatory medi-
ators and cytokines [26]. Arguably, in response to injurious
stimuli, the balance shifts from an anti-inflammatory state
towards the production and secretion of detrimental
adipocytokines such as tumour necrosis factor-α, leptin,
resistin and interleukin (IL)-6 and IL-17, which are believed
to exert local effects on the underlying coronaries and myo-
cardium [27]. Indeed, these inflammatory markers have been
implicated in the pathogenesis of LV remodelling [25]. The
local effects of EAT on the myocardium are emphasized by a
study by Hua et al. who reported an association between LV
function and EAT beyond systemic inflammatorymarkers and
serum levels of adipokines, which is in favour of a site-
specific rather than an extra-cardiac VAT effect [28]. Of inter-
est, weight loss has been shown to result in a more pro-
nounced reduction of EAT volume compared to total adiposity
measures such as BMI and the waist to hip ratio and was
significantly related to a concomitant decrease of LVM com-
pared to BMI changes, suggesting a direct mechanical or func-
tional relationship between these two anatomical compart-
ments [29]. Nevertheless, obesity itself is frequently associat-
ed with various cardiovascular risk factors and the metabolic
syndrome and is known to be associated with LVM [30, 31]. It
is therefore important to examine the impact of EAT on LVM
in subjects divided according to their obesity status. Although
EAT volume was significantly higher in patients with a BMI>
25, EATwas only associated with LVM in nonobese subjects,
after adjustment for BMI and clinical cardiovascular risk fac-
tors. These findings highlight the importance of EAT volume
in the pathogenesis of LV remodelling. Notably, this phenom-
enon has also been reported by others, whereby EAT volume
was related to incident CAD in only the nonobese patients [32,
33]. Interestingly, the study by Iwayama et al. also found
significant differences in adiponectin levels in nonobese sub-
jects according to their CAD status, while in obese patients
adiponectin was similar between patients with and without
CAD [32]. Similarly, EAT appears only to be associated with
the metabolic syndrome and coronary atherosclerosis in
nonobese patients [33]. These results highlight the importance
of EAT as a marker for cardiovascular risk. Indeed, LVM is
strongly associated with adverse outcome and the current re-
sults demonstrate that EAT might mediate LV remodelling in
otherwise healthy subjects beyond that predicted by BMI. It is
plausible that EAT might resolve the so-called obesity para-
dox, the phenomenon that obesity, as defined by BMI, does
not reflect the same burden of risk and that not all obese
individuals are similarly exposed to the same future cardio-
vascular risk [34, 35]. For instance, several studies reported
that obesity appeared to be protective against adverse outcome
Table 3 Homogeneity of






Mean±SD 3.44±1.34 3.39±1.27 3.51±1.28 0.64
COV 38.9 % 37.6 % 36.4 %
SD standard deviation, LAD left anterior descending, COV coefficient of variation
Fig. 4 Distribution of hyperaemic MBF. Histograms on the distribution of hyperaemic MBF for the left anterior descending (LAD) artery, the right
coronary artery and the circumflex coronary artery
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and associated with increased survival and reduced mortality
[35]. Interestingly, studies that used surrogatemarkers for central
adiposity such as the waist to hip ratio have depicted a different
picture [35]. An increase in central obesitywas indeed predictive
of worse outcome irrespective of BMI. Presumably, visceral
adiposity is more closely related to future cardiac events than
BMI, which is not reflective of VAT distribution and is strongly
governed by subcutaneous adipose tissue. Our present findings
indicate that EAT may explain some of the effect of obesity on
LVM in patients with cardiovascular risk factors.
In the absence of flow-limiting epicardial disease, ab-
normal myocardial perfusion is indicative of coronary mi-
crovascular dysfunction, which is considered the function-
al counterpart of coronary risk factors [36]. The exclusion
of haemodynamically significant CAD in the present pop-
ulation allows for the assessment of the coronary micro-
vascular compartment. The coronary microvasculature is
often affected by risk factors in an equal manner, thus
resulting in a homogeneously increased microvascular re-
sistance. Indeed, a homogeneous perfusion pattern was
observed in the present study population. Therefore,
quantitative PET imaging is the sole imaging modality
to detect this disease entity. The CFR is commonly used
to assess coronary vasodilator capacity, which serves as a
surrogate marker for microvascular function [19]. Howev-
er, CFR is the index of maximal achievable MBF relative
to resting perfusion and is therefore highly dependent on
baseline perfusion, which is dictated by metabolic de-
mands. Moreover, hyperaemic perfusion in turn is
governed by heart rate and coronary driving pressure,
rendering CFR a parameter that is highly affected by hae-
modynamic conditions [19]. As such, CMVR is consid-
ered a more reliable and quantitative measure of coronary
microvascular function [19]. Indeed, the present study
showed low predictive ability of the models that
employed CFR as a marker for microvascular function.
Prior studies suggest EAT to play a key role in the early
development of endothelial dysfunction [37–40]. It has
been proposed that secreted vasoactive substances by the
cardiac fat depot may influence coronary vasomotor func-
tion. This hypothesis is strengthened by a recently pub-
lished study by Bucci et al. who differentiated between
intrapericardial and extrapericardial fat and demonstrated
that hyperaemic MBF as assessed by quantitative
[15O]H2O PET was only influenced by the intrapericardial
fat depot [41]. Mechanisms linking EAT to coronary mi-
crovascular dysfunction include changes in the secretion
of adipokines, which have been related to insulin resis-
tance and a state of metabolic stress [37]. A decrease in
the cardioprotective adiponectin level reflects a pro-
atherogenic endothelial milieu with the induction of an
inflammatory response resulting in the release of pro-
inflammatory and pro-atherogenic cytokines. Indeed, re-
duced adiponectin levels have been associated with im-
paired CFR in patients with normal coronary arteries
[39]. Similarly, a study by Tok and colleagues showed
EAT to predict abnormal coronary Doppler flow measure-
ments in patients with metabolic syndrome [10]. A recent
study by Alam et al. among 137 patients without obstructive
Fig. 5 Correlations between EAT, LVM and CMVR for obese and
nonobese patients. a The relation between EAT and LVM. b The
relation between EAT and CMVR. c The relation between LVM
correlated and CMVR. EAT epicardial adipose tissue, LVM left
ventricular mass, CMVR coronary microvascular resistance
Eur J Nucl Med Mol Imaging (2015) 42:1562–1573 1569
CAD by CCTA showed EAT to be associated with im-
paired CFR as determined by 82Rb PET even after ad-
justment for traditional risk factors and coronary calci-
fications [9]. However, the current study found a mod-
erate correlation between EAT volume and CMVR. Af-
ter adjustment for traditional risk factors, only LVM was
predictive of an increased CMVR in the obese subjects.
In accordance with our findings, Brinkley et al. found
EAT not predictive of absolute MBF as determined by
MRI in asymptomatic subjects [42]. Notably, the myo-
cardium and epicardial fat share the same vasculature;
therefore, the presence of myocardial ischaemia may
provoke hypoxia of cardiac fat depot, prompting an in-
flammatory reaction within the EAT resulting in an
unfavourable anti-inflammatory/pro-inflammatory meta-
bolic condition with the subsequent secretion of vaso-
constrictive and pro-inflammatory cytokines [41]. This
may partially explain the discrepancy between EAT vol-
ume and absolute myocardial perfusion in subjects with-
out ischaemia. Noteworthy, an interesting finding by the
study of Alam et al. is the fact that EAT thickness
showed a better correlation with CFR than its volume
measurements [9]. Arguably, large portions of the EAT
are located distally from vasculature or myocardium.
Table 4 Univariable and
multivariable regression analysis
describing the relationship
between traditional cardiac risk
factors, EAT and LVM
Univariable analysis Multivariable analysis
β 95 % CI p value β 95 % CI p value
All patients (R2=0.61)
Male gender 44.3 38.3 to 50.2 <0.001 40.7 35.2 to 46.3 <0.001
Age 0.29 −0.74 to 0.17 0.21 NS
BMI 2.74 1.77 to 3.71 <0.001 1.61 0.85 to 2.37 <0.001
Diabetes 12.4 0.77 to 24.1 0.04 NS
Hypertension 7.20 −1.78 to 16.2 0.12 NS
Hypercholesterolaemia 1.47 −7.92 to 10.9 0.76 NS
Smoking 5.60 −3.06 to 14.3 0.20 6.29 0.79 to 11.8 0.03
Family history of CAD 5.10 −13.6 to 3.44 0.24 NS
EAT 0.27 0.19 to 0.35 <0.001 0.10 0.04 to 0.17 <0.01
CAC 0.01 −0.01 to 0.02 0.42 NS
Nonobese patients (R2=0.65)
Male gender 40.2 30.0 to 50.4 <0.001 30.9 22.0 to 39.8 <0.001
Age 0.58 −1.23 to 0.12 0.11 −0.54 −0.98 to 0.10 0.02
BMI 5.56 1.79 to 9.33 <0.01 NS
Diabetes 32.4 −66.4 to 1.62 0.06 NS
Hypertension 1.08 −16.0 to 18.2 0.90 NS
Hypercholesterolaemia 1.41 −19.5 to 16.7 0.88 NS
Smoking 21.1 8.1 to 34.1 <0.01 13.4 4.84 to 21.9 <0.01
Family history of CAD 9.76 −23.4 to 3.85 0.16 NS
EAT 0.30 0.16 to 0.45 <0.001 0.23 0.12 to 0.34 <0.001
CAC 0.00 −0.02 to 0.02 0.72 NS
Obese patients (R2=0.59)
Male gender 45.0 38.0 to 52.1 < 0.001 44.2 37.4 to 51.0 < 0.001
Age 0.19 −0.75 to 0.38 0.52 NS
BMI 2.43 0.94 to 3.91 < 0.01 2.03 1.04 to 3.03 < 0.001
Diabetes 13.0 052 to 25.5 0.04 NS
Hypertension 5.15 −5.51 to 15.8 0.34 NS
Hypercholesterolaemia 1.86 −12.84 to 9.12 0.74 NS
Smoking 2.19 −13.0 to 8.61 0.69 NS
Family history of CAD 5.10 −15.7 to 5.52 0.34 NS
EAT 0.22 0.12 to 0.33 < 0.001 NS
CAC 0.01 −0.01 to 0.03 0.39 NS
CI confidence interval, BMI body mass index, CAD coronary artery disease, EAT epicardial adipose tissue, LVM
left ventricular mass, CAC coronary artery calcium, NS not significant
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This is illustrated by the finding that periatrial fat, but not
periventricular fat, was associated with markers for endothelial
dysfunction in patients with atrial fibrillation [43]. Measuring
the thickness of EAT intrinsically corrects for these distal por-
tions of the visceral fat surrounding the heart and is probably a
better reflection of the vasocrine actions of this fat depot. How-
ever, measurements of EAT at a single point are highly
dependent on cardiac anatomy and may fail to reflect the total
burden of EAT. All in all, data linking EAT to coronary micro-
vascular function provide conflicting results. It is worthy to note
that the prevalence of LVM may have attenuated the relation-
ship between EAT and CMVR. A given increase in LVM,
albeit not hypertrophy, reduces the capillary density yielding
a relative hypoperfusion of the myocardium [44]. As such, the
Table 5 Univariable andmultivariable regression analysis describing the relationship between traditional cardiac risk factors, EAT, LVM and coronary
microvascular function
Univariable analysis Multivariable analysis
β 95 % CI p value β 95 % CI p value
All patients (R2=0.27)
Male gender 0.72 4.88 to 9.54 < 0.001 NS
Age 0.10 −0.04 to 0.23 0.17 NS
BMI 0.59 0.29 to 0.90 < 0.001 NS
Diabetes 4.61 1.19 to 8.03 < 0.01 NS
Hypertension 3.41 0.77 to 6.06 0.01 NS
Hypercholesterolaemia 3.17 0.39 to 5.94 0.03 2.52 0.10 to 4.93 0.04
Smoking 1.44 −1.15 to 4.02 0.27 NS
Family history of CAD 0.86 −3.41 to 1.69 0.51 NS
EAT 0.05 0.02 to 0.07 < 0.001 NS
LVM 0.14 0.10 to 0.18 < 0.001 0.14 0.10 to 0.17 < 0.001
CAC 0.01 0.00 to 0.01 < 0.01 0.01 0.00 to 0.01 < 0.01
Nonobese patients (R2=0.19)
Male gender 5.65 1.76 to 9.54 < 0.01 5.09 1.29 to 8.89 < 0.01
Age 0.01 −0.21 to 0.22 0.97 NS
BMI 0.01 −1.16 to 1.19 0.98 NS
Diabetes 1.09 −11.3 to 9.15 0.83 NS
Hypertension 4.20 −0.73 to 9.13 0.09 NS
Hypercholesterolaemia 0.27 −5.58 to 5.04 0.92 NS
Smoking 6.00 2.16 to 9.85 < 0.01 5.54 1.80 to 9.28 < 0.01
Family history of CAD 1.23 −5.29 to 2.84 0.55 NS
EAT 0.02 −0.03 to 0.07 0.41 NS
LVM 0.09 0.03 to 0.16 < 0.01 NS
CAC 0.00 −0.00 to 0.01 0.17 NS
Obese patients (R2=0.32)
Male gender 7.54 4.66 to 10.4 < 0.001 NS
Age 0.13 −0.04 to 0.30 0.13 NS
BMI 0.53 0.07 to 0.99 0.03 NS
Diabetes 4.05 0.32 to 7.79 0.03 NS
Hypertension 2.04 −1.16 to 5.24 0.21 NS
Hypercholesterolaemia 3.43 0.15 to 6.70 0.04 2.94 0.12 to 5.75 0.04
Smoking 0.85 −4.11 to 2.42 0.61 NS
Family history of CAD 1.36 −4.56 to 1.84 0.40 NS
EAT 0.05 0.02 to 0.08 < 0.01 NS
LVM 0.15 0.11 to 0.20 < 0.001 0.15 0.10 to 0.19 < 0.001
CAC 0.01 0.00 to 0.02 < 0.01 0.01 0.00 to 0.01 <0.01
CI confidence interval, BMI body mass index, CAD coronary artery disease, EAT epicardial adipose tissue, LVM left ventricular mass, CAC coronary
artery calcium, NS not significant
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contentious association between EAT and its impact on coro-
nary microvasculature may be justified by the relation be-
tween EAT and LVM. Earlier studies examining the impact
of EAT on coronary vasculature have not accounted for the
impact of LVM. Furthermore, prior studies have only exclud-
ed obstructive epicardial disease by means of CCTA, which
may have resulted in the inclusion of patients with myocardial
ischaemia.
Study limitations
Other than the limitations inherent to the retrospective nature
of the study, some limitations must be acknowledged. First,
only EAT has been examined and therefore systemic effects of
other visceral fat depots could not be fully excluded. Although
the relation between EAT and other visceral fat depots was
demonstrated previously, distinct visceral fat origins may ex-
ert different effects on the myocardium and coronary micro-
vasculature. Second, data on the prevalence of the metabolic
syndrome among study participants were not available and
might have provided a better understanding of the relationship
between EAT, LVM and CMVR. Third, it is likely that the
volumetric amount of EAT does not fully reflect the biochem-
ical properties of this visceral fat depot. Therefore, the assess-
ment of EAT characteristics such as cytokine production, in-
flammation and/or perfusion might have provided valuable
insights. Finally, the applied cut-off value for obesity (BMI≥
25) is arbitrary. However, the included patients were free from
obstructive CAD and represent therefore a low-risk popula-
tion. As such, there were only 35 individuals with a BMI>30.
The use of this threshold would have resulted in overfitting of
the regression models
Conclusion
EAT volume is associated with LVM independently of BMI
and might therefore be a better predictor of cardiovascular risk
than BMI. However, EAT provides no incremental informa-
tion on coronary microvascular function beyond traditional
risk factors and LVM. An increased CMVR is only associated
with LVM in the obese subjects.
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